CAS：960539-70-2
Chemical formula: C19H27N3O6

1.Specifications, usage, and dosage
Specifications:Tablets: 1mg, 2mg, 4mg, 6mg, 8mg;

Usage and dosage:
. Patients with conservative chronic kidney disease
The commonly used starting dose for adults without treatment with red blood cell hematopoietic stimulating factor preparations is 2mg or 4mg, taken orally once a day. Afterwards, the dosage can be adjusted according to the patient's condition, but the maximum dosage should be 24mg once a day.
When switching from red blood cell hematopoietic stimulating factor preparations, the usual adult dose is 4mg orally once a day. The dose can be adjusted according to the patient's condition, but the maximum dose should be 24mg once a day.
. Dialysis patients
The usual adult dose is 4mg orally once a day, and the dose can be adjusted according to the patient's condition, but the maximum dose should be 24mg once a day.
2.Indications
Indications: Used to treat anemia caused by chronic kidney disease in adults who have undergone dialysis for at least four months.
3.Product advantages
A novel oral hypoxia inducible factor proline hydroxylase inhibitor (HIF-PHI) is also the first FDA approved oral therapy for anemia caused by chronic kidney disease, used to treat non dialysis dependent (NDD) and dialysis dependent (DD) adult chronic kidney disease anemia;
The Phase III clinical results indicate that dapagliptin has shown positive efficacy in treating adult patients with non dialysis dependent (NDD) and dialysis dependent (DD) chronic kidney disease (CKD) anemia, without increasing cardiovascular risk;
This product benefits patients by stimulating the bone marrow to produce more red blood cells, and the oral dosage form is highly compliant, avoiding injection administration and refrigeration requirements;
The compound patent is about to expire in 2027, and it will first be listed in Japan in 2020. Currently, there are only original research applications in China, and our company can provide general agents for foreign raw materials. Please feel free to inquire.